ERS Genomics and genOway enter CRISPR/Cas9 agreement
Dublin, Ireland and Lyon, France, 07 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and genOway, a leader in conceiving and developing genetically engineered preclinical research models, today announced a non-exclusive licence agreement granting genOway past and future access to…
MHRA confirms registration of Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the MHRA has confirmed registration of Avacta’s AffiDX® SARS-CoV-2 antigen lateral flow test, allowing the Company to place the product on the market in the UK for professional use.
Iksuda Therapeutics closes $47 million financing round
Newcastle, UK, 07 June 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support…
Japanese Patent Office upholds key Charpentier/Doudna CRISPR patent and allows third
Dublin, Ireland, 01 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, today announced that the Japanese Patent Office (JPO) has rejected arguments filed in opposition to the second Japanese patent (JP6692856) filed by Dr.Charpentier, together with The Regents of the University of…
GammaDelta Therapeutics receives FDA Clearance of IND Application for GDX012, a novel allogeneic variable delta 1 gamma-delta T cell cancer therapy
GammaDelta Therapeutics, a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy, today announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological…
Optibrium and BioPharmics enter partnership on computational drug design
Industry-leading 3D ligand-based design approaches from BioPharmics will be available in StarDrop, Optibrium’s small molecule design and optimisation software.
Charles Fracchia selected for DARPA ISAT Study Group
Boston, US, 18th May 2021: Dotmatics, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced that the US Defense Advanced Research Projects Agency (DARPA) has named Charles Fracchia, Founder of Dotmatics BioBright, to its Information Science and Technology (ISAT) Study…
ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 licence agreement
Dublin, Ireland and Piscataway, New Jersey, 12 May 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and GenScript Biotech Corporation (GenScript), the world’s leading research reagent provider, today announced a non-exclusive licence agreement granting GenScript access to ERS Genomics’…
FUJIFILM Irvine Scientific celebrates 50 years of excellence in cell culture
FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing innovative cell culture media products and services. Since its formation, the Company has established a reputation as an innovator and leader in providing cell culture solutions for the Life Science and Medical markets.
Hubrecht Institute licenses Flow Eighteen38 reagent antibodies for cancer research
Porto, Portugal and Utrecht, Netherlands... Flow Eighteen38 and FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, have today announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools for the group of Hans Clevers.
Bio-Rad launches its Reliance SARS-CoV-2 RT-PCR Assay Kit in Europe
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2 RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.
H.E.L Group appoints Sales Director for Asia-Pacific
H.E.L Group , a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today announced the appointment of Oh Chee Keat (Brice Oh) as Regional Sales Director for Asia-Pacific.
Turbine strengthens R&D capabilities with key appointments
London, UK, Budapest, Hungary... Turbine, a company developing a cell behavior simulation platform to uncover targets for the most challenging cancers, today announced that it has appointed Dr. Mark Velleca as Chair of the Board of Directors. The company also announced that Professor Gordon Mills and Dr Klaus Hoeflich have joined its Scientific Advisory Board (SAB). Drawing on their combined…
H.E.L Group signs distribution agreement with ThalesNano Energy for H-Genie bench-top high-pressure hydrogen generator
London, UK, 27th April 2021: H.E.L Group, a global developer and manufacturer of innovative laboratory tools for process optimisation, safety and scale-up, today announced that it has signed a worldwide non-exclusive distribution agreement with ThalesNano Energy™, a developer of bench-top chemistry-focused gas generators. Covering the H-Genie® bench-top hydrogen generator and associated…
Avacta receives clinical validation of AffiDX SARS-CoV-2 antigen lateral flow test
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce positive data from the clinical validation of its AffiDX® SARS-CoV-2 antigen lateral flow test. Data from the clinical study conducted in Europe on 98 positive COVID-19 samples demonstrate excellent performance in…
Adaptate Biotherapeutics raises $18 million in Series A2 funding
London, UK... Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited have together made a further equity investment of $18 million (circa. £13 million). This funding brings the total raised since Adaptate’s inception in late…
ERS Genomics and NUVISAN ICB sign CRISPR/Cas9 licence agreement
CRISPR offerings to enhance NUVISAN’s drug development service portfolio.
Arkema chooses Dotmatics as R&D digitalization partner
Bishop’s Stortford, UK: Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has been selected by Arkema, a global leader in speciality materials, as its informatics partner in an R&D digitalization project. Implementing Dotmatics’ unified…
FairJourney Biologics enters next-generation antibody discovery collaboration with argenx
Porto, Portugal, and Cambridge and London, UK: FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimisation of VHH fully human antibodies, today announced a collaboration with global immunology company, argenx to harness IONTAS’ proprietary mammalian display technology. The goal of the collaboration is to explore diverse panels of novel antibody…
Mologic’s COVID-19 rapid antigen self-test selected by NIH for RADx initiative funding
Mologic, a leading developer of lateral flow and rapid diagnostic technologies, announced its rapid antigen self-test for COVID-19 has been selected by the Rapid Acceleration of Diagnostics (RADxSM) initiative launched by the US National Institutes of Health (NIH). The initiative aims to speed innovation in the development, commercialisation, and implementation of technologies for COVID-19…
Avacta announces distribution agreement with Abcam plc
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with Abcam plc (AIM: ABC; NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.
Dotmatics implements ‘Data to Value’ initiative with BASF Agricultural Solutions
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced the implementation of a ‘Data to Value’ initiative with BASF’s Agricultural Solutions division.
Insightful Science joins forces with Dotmatics to form a leading cloud-first scientific R&D company
Bishop’s Stortford, UK and San Diego, CA— Insightful Science, a leading software provider serving the global life sciences community, announced that it has entered into a transaction to acquire Dotmatics, an industry leading cloud-based scientific R&D data management platform.
IONTAS identifies novel SARS-CoV-2 neutralising antibodies
Cambridge, UK, Porto, Portugal, and London, UK – IONTAS Limited and FairJourney Biologics SA (FJB), leaders in the discovery and optimisation of fully human antibodies, have announced the identification of neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants.
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test
York and Bedfordshire, UK...Aptamer Group, the developer of diagnostic and therapeuticOptimer reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.